Abstract
To test the anti-tumour activity of rhizoxin in recurrent and/or metastatic squamous cell head and neck cancer, we performed a phase II study. Eligibility required histologically proven squamous cell head and neck cancer. Patients could only have received one prior chemotherapy. Patients were entered if WHO PS was < or = 2 and organ functions were normal. Treatment consisted of rhizoxin 1.5-2.0 mg m-2 i.v. bolus injection once every 3 weeks. Thirty-two patients entered the study. All were eligible, 31 were evaluable for toxicity and 25 for response. Toxicity mainly consisted of pain at the tumour site and leucocytopenia. Mild asthenia and stomatitis were also observed. Two objective partial responses, lasting 7.5 and 3.5 months, were seen. Rhizoxin at this dose and schedule has minor activity in recurrent and/or metastatic squamous cell head and neck cancer.
Full text
PDF
Selected References
These references are in PubMed. This may not be the complete list of references from this article.
- Bissett D., Graham M. A., Setanoians A., Chadwick G. A., Wilson P., Koier I., Henrar R., Schwartsmann G., Cassidy J., Kaye S. B. Phase I and pharmacokinetic study of rhizoxin. Cancer Res. 1992 May 15;52(10):2894–2898. [PubMed] [Google Scholar]
- Clavel M., Maged Mansour A. R. Head and neck cancer: prognostic factors for response to chemotherapy. Eur J Cancer. 1991;27(3):349–356. doi: 10.1016/0277-5379(91)90544-n. [DOI] [PubMed] [Google Scholar]
- Hendriks H. R., Plowman J., Berger D. P., Paull K. D., Fiebig H. H., Fodstad O., Dreef-van der Meulen H. C., Henrar R. E., Pinedo H. M., Schwartsmann G. Preclinical antitumour activity and animal toxicology studies of rhizoxin, a novel tubulin-interacting agent. Ann Oncol. 1992 Nov;3(9):755–763. doi: 10.1093/oxfordjournals.annonc.a058334. [DOI] [PubMed] [Google Scholar]
- Iwasaki S., Kobayashi H., Furukawa J., Namikoshi M., Okuda S., Sato Z., Matsuda I., Noda T. Studies on macrocyclic lactone antibiotics. VII. Structure of a phytotoxin "rhizoxin" produced by Rhizopus chinensis. J Antibiot (Tokyo) 1984 Apr;37(4):354–362. doi: 10.7164/antibiotics.37.354. [DOI] [PubMed] [Google Scholar]
- Kiyoto S., Kawai Y., Kawakita T., Kino E., Okuhara M., Uchida I., Tanaka H., Hashimoto M., Terano H., Kohsaka M. A new antitumor complex, WF-1360, WF-1360A, B, C, D, E and F. J Antibiot (Tokyo) 1986 Jun;39(6):762–772. doi: 10.7164/antibiotics.39.762. [DOI] [PubMed] [Google Scholar]
- Takahashi M., Iwasaki S., Kobayashi H., Okuda S., Murai T., Sato Y. Rhizoxin binding to tubulin at the maytansine-binding site. Biochim Biophys Acta. 1987 Dec 7;926(3):215–223. doi: 10.1016/0304-4165(87)90206-6. [DOI] [PubMed] [Google Scholar]
- Tsuruo T., Oh-hara T., Iida H., Tsukagoshi S., Sato Z., Matsuda I., Iwasaki S., Okuda S., Shimizu F., Sasagawa K. Rhizoxin, a macrocyclic lactone antibiotic, as a new antitumor agent against human and murine tumor cells and their vincristine-resistant sublines. Cancer Res. 1986 Jan;46(1):381–385. [PubMed] [Google Scholar]